Evidence map›Paper›PMID 24726882›Full record

ArticleBiochimica et biophysica acta2014

Induction of ATM/ATR pathway combined with Vγ2Vδ2 T cells enhances cytotoxicity of ovarian cancer cells.

Jingwei Lu, Manjusri Das, Suman Kanji, Reeva Aggarwal, Matthew Joseph, Alo Ray, Charles L Shapiro, Vincent J Pompili, Hiranmoy Das

Open access · greenAbstract read
In one paragraph

Article in Biochimica et biophysica acta, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Jingwei LuDepartment of Internal Medicine, Wexner Medical Center at the Ohio State University, Columbus, OH 43210, USA.
Manjusri DasDepartment of Internal Medicine, Wexner Medical Center at the Ohio State University, Columbus, OH 43210, USA.
Suman KanjiDepartment of Internal Medicine, Wexner Medical Center at the Ohio State University, Columbus, OH 43210, USA.
Reeva AggarwalDepartment of Internal Medicine, Wexner Medical Center at the Ohio State University, Columbus, OH 43210, USA.
Matthew JosephDepartment of Internal Medicine, Wexner Medical Center at the Ohio State University, Columbus, OH 43210, USA.
Alo RayDepartment of Internal Medicine, Wexner Medical Center at the Ohio State University, Columbus, OH 43210, USA.
Charles L ShapiroDepartment of Breast Program, Wexner Medical Center at the Ohio State University, Columbus, OH 43210, USA.
Vincent J PompiliDepartment of Internal Medicine, Wexner Medical Center at the Ohio State University, Columbus, OH 43210, USA.
Hiranmoy DasDepartment of Internal Medicine, Wexner Medical Center at the Ohio State University, Columbus, OH 43210, USA; Innate Immunity, Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Wexner Medical Center at The Ohio State University, Columbus, OH 43210, USA. Electronic address: hiranmoy.das@osumc.edu.
The Ohio State University Wexner Medical Center · USThe Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute · US

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI WANCAI YANG · 1985 to 2026
$132.3M
Therapeutic Potential of Ex vivo expanded Human Cord Blood derived CD133+ cells iR44HL092706 · NHLBI · ARTERIOCYTE, INC. · PI COOPER, CHRISTOPHER J, POMPILI, VINCENT J · 2008 to 2011
$2.5M
KLF2 as a novel regular for monocyte activation and functionK01AR054114 · NIAMS · OHIO STATE UNIVERSITY · PI DAS, HIRANMOY · 2008 to 2012
$670k
Novel Markers of Anthracycline-induced Myocardial DamageR21CA143787 · NCI · OHIO STATE UNIVERSITY · PI SHAPIRO, CHARLES L. · 2010 to 2011
$632k
NCI NIH HHS P30 CA016058NCI NIH HHS R21 CA143787NHLBI NIH HHS R44 HL092706NHLBI NIH HHS R44 HL092706-01NIAMS NIH HHS K01 AR054114
6 · The paper itself

Abstract

Many ovarian cancer cells express stress-related molecule MICA/B on their surface that is recognized by Vγ2Vδ2 T cells through their NKG2D receptor, which is transmitted to downstream stress-signaling pathway. However, it is yet to be established how Vγ2Vδ2 T cell-mediated recognition of MICA/B signal is transmitted to downstream stress-related molecules. Identifying targeted molecules would be critical to develop a better therapy for ovarian cancer cells. It is well established that ATM/ATR signal transduction pathways, which is modulated by DNA damage, replication stress, and oxidative stress play central role in stress signaling pathway regulating cell cycle checkpoint and apoptosis. We investigated whether ATM/ATR and its down stream molecules affect Vγ2Vδ2 T cell-mediated cytotoxicity. Herein, we show that ATM/ATR pathway is modulated in ovarian cancer cells in the presence of Vγ2Vδ2 T cells. Furthermore, downregulation of ATM pathway resulted downregulation of MICA, and reduced Vγ2Vδ2 T cell-mediated cytotoxicity. Alternately, stimulating ATM pathway enhanced expression of MICA, and sensitized ovarian cancer cells for cytotoxic lysis by Vγ2Vδ2 T cells. We further show that combining currently approved chemotherapeutic drugs, which induced ATM signal transduction, along with Vγ2Vδ2 T cells enhanced cytotoxicity of resistant ovarian cancer cells. These findings indicate that ATM/ATR pathway plays an important role in tumor recognition, and drugs promoting ATM signaling pathway might be considered as a combination therapy together with Vγ2Vδ2 T cells for effectively treating resistant ovarian cancer cells.

Indexed as

Antineoplastic AgentsAtaxia Telangiectasia Mutated ProteinsCell Line, TumorDown-RegulationFemaleHistocompatibility Antigens Class IHumansOvarian NeoplasmsOxidative StressReactive Oxygen SpeciesReceptors, Antigen, T-Cell, gamma-deltaSignal TransductionT-LymphocytesAntineoplastic AgentsAtaxia Telangiectasia Mutated ProteinsATM protein, humanATR protein, humanHistocompatibility Antigens Class IMHC class I-related chain AReactive Oxygen SpeciesReceptors, Antigen, T-Cell, gamma-deltaATM/ATR pathwayCombination therapyCytotoxicityMICAOvarian cancerVγ2Vδ2 T cells

Identifiers

PMID24726882
PMCPMC4082796
OpenAlexW1972799837

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.